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Abstract
AIM: The expression pattern of endoglin (CD105) in
hepatocellular carcinoma (HCC) has not been reported so
far. We hypothesized that CD105 could differentially
highlight a subset of microvessels in HCC, and intratumoral
microvessel density (IMVD) by CD105 immunostaining
(IMVD-CD105) could provide better prognostic information
than IMVD by CD34 immunostaining (IMVD-CD34).
METHODS: Paraffin blocks of tumor and adjacent non-
tumorous liver tissues from 86 patients who underwent
curative resection of HCC were used for this study. Serial
sections were stained for CD105 and CD34, respectively,
to highlight the microvessels. IMVD was counted according
to a standard protocol.
RESULTS:  In the HCC tissues, CD105 was either negatively
or positively stained only in a subset of microvessels. In
contrast, CD34 showed positive and more extensive
microvessel staining in all cases examined. However, in
the adjacent non-tumorous liver sections, CD105 showed
a diffuse pattern of microvessel staining in 20 of 86 cases,
while CD34 showed negative or only focal staining of the
sinusoids around portal area. Correlat ion with
clinicopathological data demonstrated that lower scores
of IMVD-CD105 were found in larger sized tumors
[mean 41.4/0.74 mm2 (>5 cm tumor) vs 65.9/0.74 mm2
( 5 cm tumor), P = 0.043] and more aggressive tumors,
as indicated by venous infiltration [36.8/0.74 mm2 (present)
vs 64.2/0.74 mm2 (absent), P = 0.020], microsatellite
nodules [35.1/0.74 mm2 (present) vs 65.9/0.74 mm2
(absent), P = 0.012], and advanced TNM tumor stage
[38.8/0.74 mm2 (stage 3 or 4) vs 68.3/0.74 mm2 (stage 1
or 2), P = 0.014]. No prognostic significance was observed
when median values were used as cut-off points using
either IMVD-CD105 or IMVD-CD34. However, the presence
of the diffuse pattern of CD105 expression in the adjacent
non-tumorous liver tissues predicted a poorer disease-free
survival (median 8.6 vs 21.5 mo, P = 0.026).
CONCLUSION: Our data demonstrate that a lower IMVD-
CD105 is associated with larger and more aggressive
tumors. In this study, IMVD-CD105 did not provide
significant prognostic information. However, active
angiogenesis as highlighted by diffuse CD105 staining of
the microvessels in the adjacent non-tumorous liver tissues
is predictive of early recurrence.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Angiogenesis, the formation of new capillaries from a pre-
existing vasculature, is implicated in tumor development, growth,
progression, and metastasis[1-3]. Different from that in the normal
physiological condition, the fine balance of modulation between
proangiogenic and antiangiogenic factors is disturbed in tumor
microenvironment, thus leading to abnormal vessel growth.  It
is known that tumor-associated endothelial cells in the
neovasculature proliferate 20 to 2000 times more rapidly than
those found in the normal vasculature[4,5]. The characteristics
of microvessels in tumors are different from that developed
under normal physiological conditions[6]. In fact, intratumoral
microvessel density (IMVD) has been extensively investigated
and was found to be a useful prognostic marker in many types
of cancers[7].
      Hepatocellular carcinoma (HCC) is a highly vascularized
tumor on angiography. Its neovascularization is featured by
sinosoidal capillarization[8]. However, not much is known about
the exact mechanism and contribution of angiogenesis in
different stages of HCC development. Several studies have
shown that certain endothelial markers, in particular CD34, are
expressed diffusely in the microvessels of HCC, and that their
levels of expression correlate with prognosis of the patients[9-11].
A previous study by our group showed that IMVD assessed
by CD34 immunostaining (IMVD-CD34) was a good prognostic
marker of recurrence after hepatectomy in patients whose
tumors were less than or equal to 5 cm in diameter[11].  However,
CD34 is a pan-endothelial cell marker that reacts not only with
proliferating vessels but also with established vessels in the
tumor. Therefore, CD34 might not be an ideal marker of tumor
neovascularization in HCC.
        Endoglin (CD105) is a homodimeric membrane glycoprotein
expressed on endothelial cells that can bind to transforming
growth factor-β1 and transforming growth factor-β3[12]. CD105
is only weakly expressed in normal tissues, but it is strongly
expressed in tumor endothelia[13-18]. Recent studies have
suggested that CD105 is a proliferation-associated marker of
endothelial cells[13], and that its expression correlates strongly
with cell proliferation markers in tumor endothelia[12]. Moreover,
CD105 has been demonstrated to be a good tumor angiogenesis
marker in breast cancer[19], brain tumor[20], malignant melanoma[21]
and colorectal carcinoma[22]. Detection of CD105 in endothelial
cells by immunohistochemical staining has been reported to
provide a superior angiogenesis marker compared with the
conventional CD34 staining in non-small cell lung cancer[18] and
multiple myeloma[23]. Evaluation of tumor tissue expression of
CD105 in correlation with clinicopathological parameters has
revealed its diagnostic and prognostic significance in cancers
such as breast cancer[24,25], squamous cell carcinoma of the oral
cavity[26], prostate cancer[27], and renal cell carcinoma[28].
       To date, not much is known about the exact mechanism of
tumor angiogenesis in HCC, and the expression pattern of
CD105 in HCC has not been reported before. Supported by the
evidence shown in other tumors, we hypothesized that CD105
might be able to differentially highlight a subset of newly
sprouted and immature microvessels in HCC, and tumor IMVD
by CD105 immunostaining (IMVD-CD105) might provide a more
informative angiogenesis score than IMVD-CD34, especially
in terms of correlation with clinicopathological parameters.
MATERIALS AND METHODS
Patients and tissue samples
Eighty-six patients (67 men, 19 women) who underwent curative
resection of HCC, defined as macroscopically complete removal
of the tumor, in the Department of Surgery of the University of
Hong Kong at Queen Mary Hospital were studied. None of the
patients had received any preoperative treatment such as
transarterial chemoembolization, and no postoperative adjuvant
therapy was given. The study was approved by the Institutional
Review Board of our institution.
      The mean±SD maximum diameter of the tumors was 8.0 +/-
5.0 cm (range 1.5 cm to 22.0 cm). Thirty-three patients (38%)
had tumor 5 cm in diameter. Tissue specimens were taken
from the tumors and from adjacent non-tumorous livers. Fresh
tissue specimens were fixed in 10% buffered formalin and
embedded in paraffin, and 4-µm-thick sections were prepared
for immunohistochemical study.
Immunohistochemical staining for CD34 and CD105
Tumorous and non-tumorous sections were immunostained
with human CD34 monoclonal antibody (1:100; QBEND-10,
Dako, Carpenteria, CA, USA) and CD105 monoclonal antibody
(1:1 000; SN6H, Dako, Carpenteria, CA, USA). Consecutive
paraffin sections were used for the staining of CD34 and
CD105.  Vascularizat ion was demonstrated by an
immunohistochemical analysis for CD105 using a catalyzed
signal amplification system (Dako), based on the peroxidase-
catalyzed deposition of a biotinylated phenol compound
tyraminde, while LSAB kit from Dako was used for CD34
staining. The negative controls were obtained by substituting
the primary antibodies with mouse immunoglobulin G. IMVD
was evaluated according to Gasparini’s criteria[29] by two
independent observers as described in a previous report[11].
The mean microvessel count of the five most vascular areas
was taken as the MVD, which was expressed as the absolute
number of microvessels per 0.74 mm2 (×200 field).
Clinicopathological and follow-up data
All clinicopathological data were collected prospectively in a
computerized database, and all patients were followed and
monitored regularly for tumor recurrence by serum alpha
fetoprotein (AFP) level monthly and chest X-ray together with
computed tomography (CT) scan every 3 mo. The median follow-
up time of all patients was 36 mo (range 20 to 50 mo). A diagnosis
of recurrence was based on typical imaging appearance in CT
scan and an elevated AFP level, and if necessary, fine needle
aspiration cytology.
Statistical analysis
Student t-test was used for comparison of continuous variables
between groups. The correlation between continuous variables
was performed using the Spearman rank correlation test.
Cumulative disease-free survival was computed using the
Kaplan-Meier method and comparison between groups was
done by the log-rank test.
       Clinicopathological variables that were correlated with IMVD
included gender, age ( or >60 years), hepatitis B surface
antigen (HBsAg) status, presence or absence of cirrhosis in
the non-tumorous livers, tumor size (  or >5 cm), tumor
differentiation by Edmonson grade (1-2 or 3-4), any tumor
encapsulation, venous invasion, microsatellite nodules, and
pTNM stage (I/II or III/IVA). All statistical analyses were
performed using the SPSS statistical software (SPSS/PC+, SPSS
Inc., Chicago, IL, USA). P < 0.05 was considered statistically
significant.
RESULTS
CD105 and CD34 staining in tumor and adjacent non-tumorous liver
Figure 1 shows the typical staining patterns of CD105
immunostaining in the tumor and the adjacent non-tumorous
sections of the liver. The mean score of IMVD-CD105 was
50.8±54.8/0.74 mm2 (range 0-240.0), whereas the mean score of
IMVD-CD34 was 125.6±53.2/0.74 mm2 (range 28.2-283.4) (P < 0.001).
There were no significant differences between IMVD values
obtained by the two independent scorers.
      Results from this study of 86 HCC cases revealed some
similarities but also some differences between CD34 and CD105
staining.  Similar to the CD34 staining observed in the present
study, and that from others reported in HCC[9-11,30], highlighted
microvessels by CD105 also showed three patterns of expression
on the tumor tissue sections: sinusoid-like, branching, and small
without apparent lumina (endothelial sprouts).  Distinctively,
the expression pattern of CD105 in HCC differed from that of
CD34 in the following aspects. First, when consecutive slides
of tumor tissue sections were compared, the number of vessels
highlighted by CD105 was considerably lower than that by
CD34, although a statistically significant positive correlation
was observed between the MVD scores by the two markers
(Figure 2). Second, in all tumor sections examined, CD105 was
completely negative in 28/86 cases, while CD34 was positive in
all of the cases examined. Third, in non-tumorous tissues,
CD105 showed variable patterns of staining, including a diffuse
pattern of staining in some cases, whereas CD34 was uniformly
negative in non-tumorous liver except for sparse sinusoid
staining distributed focally around the portal tract.
Correlation between IMVD and clinicopathological parameters
Table 1 summarizes the analysis of IMVD-CD105 and IMVD-
CD34 in relation to various clinicopathological parameters. No
significant differences were found between either IMVD-CD105
or IMVD-CD34 and gender, age or hepatitis B infection status
of the patients. However, IMVD-CD105 and IMVD-CD34 were
significantly related to several pathological variables. Both
IMVD-CD105 and IMVD-CD34 were significantly lower in
tumors > 5 cm compared to tumors 5 cm in diameter (P = 0.043
and 0.002, respectively). Furthermore, both showed a significant
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Figure 1  Expression of CD105 and CD34 as shown by the brown staining of the vasculature in tumor and adjacent non-tumorous
liver (×100). A-C are serial sections of tumor tissue, where A shows the CD34 expression, B shows the CD105 expression, and C
shows the negative control. D and E are serial sections of adjacent non-tumorous liver, where D shows the CD34 expression, and
E shows the CD105 expression. Both D and E illustrate typical focal staining of vessels around the portal vein. F shows a case of
diffuse CD105 staining in the non-tumorous liver, whereas such pattern of staining was not seen in the non-tumorous liver by
CD34 staining.
Table 1  Correlation of IMVD-CD105 and IMVD-CD34 with clinicopathological parameters
                                                             IMVD-CD105 (/0.74 mm2)                                                IMVD-CD34 (/0.74 mm2)
Clinical parameters
                                                   n              mean               SD                    P                     n                      mean                 SD                P
Gender
  Male 67      49.29   55.17 0.631 67 124.94 53.51       0.823
  Female 19      56.19   54.40 19 128.07 53.54
Age (yr)
  60 years 58      43.96   48.21 0.095 58 121.09 58.19       0.257
  >60 years 28      65.01   64.99 28 135.04 40.39
HBsAg
  Positive 69      46.35   49.36 0.121 69 121.52 53.02       0.227
  Negative 17      70.08   73.87 17 139.37 52.48
Histopathological parameters
Tumor size
   5 cm 33      65.90   58.98 0.043 33 147.76 53.41       0.002
  >5 cm 53      41.42   50.26 53 111.85 48.68
Tumor encapsulation
  Absent 53      48.31   48.00 0.497 53 120.29 54.19       0.193
  Present 33      56.72   65.04 33 135.94 52.01
Venous invasion
  Absent 44      64.17   60.96 0.020 44 133.59 50.14       0.157
  Present 42      36.83   43.91 42 117.29 55.64
Microsatellite lesions
  Absent 48      65.88   62.15 0.012 48 129.63 52.55       0.401
  Present 38      35.06   41.02 38 119.65 52.53
Adjacent non-tumorous liver
  Normal (0)   6      59.26   52.46 0.602 (0&1)   6 102.95 40.09       0.602 (0&1)
  Chronic hepatitis (1) 38      43.14   57.47 0.817 (0&2) 38 118.37 47.69       0.118 (1&2)
  Cirrhosis (2) 42      53.84   53.49 0.537 (1&2) 42 135.44 58.31       0.158 (0&2)
Edmonson grade
  1 & 2 21      83.73   65.87 0.079 21 162.94 41.95       0.013
  3 65      48.47   54.21 65 117.28 51.12
TNM stage
  I & II 35      68.26   63.67 0.014 35 144.89 55.42       0.005
  III & IVA 51      38.84   44.52 51 112.41 47.84
HBsAg, hepatitis B surface antigen; TNM, tumor-node-metastasis.
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correlation with pTNM staging, and a lower IMVD observed in
tumors with more advanced staging (P = 0.014 and 0.005,
respectively). However, only lower scores of IMVD-CD105
showed a statistically significant association with venous
invasion [36.8/0.74 mm2 (present) vs 64.2/0.74 mm2 (absent),
P = 0.02], and microsatellite nodules [35.1/0.74 mm2 (present)
vs 65.9/0.74 mm2 (absent), P = 0.012].
Figure 2  Graph of scatter plots showing correlation between
scores of IMVD-CD105 vs IMVD-CD34.
Disease-free survival analysis
Disease-free survival analysis was performed in 81 patients
after 5 patients with hospital mortality or palliative resection
(i.e. positive resection margin) were excluded. No prognostic
significance was observed when median values were used as
cut-off points using either IMVD-CD105 or IMVD-CD34.
However, as shown in Figure 3, when the patients were
segregated by the presence and absence of diffuse CD105
staining patterns in the adjacent non-tumorous liver tissues,
the patients with diffuse CD105 staining in the adjacent non-
tumorous livers had a much poorer prognosis than those
patients without such a pattern of CD105 staining (median
disease-free survival 8.6 vs 21.5 mo, P = 0.026).
Figure 3  Disease-free survival analysis shows the differences
in disease-free survival in patients with or without diffuse
pattern of CD105 staining in non-tumorous livers. Five pa-
tients were excluded from the analysis because of hospital
mortality or palliative resection with positive resection
margins.
DISCUSSION
Previous reports have demonstrated that IMVD-CD34 is a better
prognostic marker for HCC than IMVD assessed by many other
endothelial markers, such as von Willebrand marker (vWF),
CD31, and UEA-1[10,11,31]. However, CD34 is a pan-endothelial
cell marker, therefore, it may not be able to reflect the exact
angiogenesis activity in a tumor. According to some previous
reports, CD105 is an endothelial marker that appears to react
only with the endothelial cells in the newly formed vessels, and
in particular, the immature tumor blood vessels[13-18]. Moreover,
studies in other cancers have suggested that scores of IMVD-
CD105 might be superior to those of IMVD-CD34 in terms of
prognostic information[18,23]. To our knowledge, this is the first
study that evaluated the clinicopathological significance of
IMVD-CD105 in HCC, which is of particular interest because
HCC is one of the most vascular solid tumors. Overall, in
agreement with those reported for other cancers in the literature,
our immunostaining confirmed that CD105 could stain a subset
of microvessels and the staining patterns of CD105 in both
tumors and non-tumorous liver differed from those stained by
CD34 in certain aspects.
      Correlation with clinicopathological parameters in this study
demonstrated significantly lower IMVD scores in larger and
more advanced stage tumors with both CD105 and CD34 as the
endothelial markers. Moreover, lower scores of IMVD-CD105
were associated with more aggressive tumors as indicated by
microscopic venous invasion and microsatellite nodules (Table 1).
The latter correlations were probably indirect ones related to
the higher frequencies of microscopic venous invasion and
microsatellite nodules in larger tumors. The findings of a
clinicopathological correlation with IMVD-CD105 were
apparently contrary to those reported in other solid tumor types
such as breast cancer and non-small cell lung cancer[18,24,25], in
which higher rather than lower IMVD scores were associated
with more aggressive tumors. However, as reviewed by
Gasparini et al.[32], most retrospective studies in breast cancer
were on early-stage tumors, and hence angiogenesis appears
to be a good prognostic marker only in early-stage group of
breast cancer.  Similarly, our previous study also illustrated
that IMVD-CD34 was a good prognostic marker in small tumors
5 cm only[11]. The HCC cases studied by Tanigawa et al.[10],
who demonstrated a worse prognosis with a higher IMVD-
CD34, were also mainly small tumors 5 cm in diameter. In this
study, the majority of tumors were >5 cm in diameter, and both
IMVD-CD105 and IMVD-CD34 decreased with increase in tumor
size. In support of our data, the IMVD-CD34 analysis of 71
HCC cases by El-Assal et al.[9] also found that the larger (>5 cm)
tumors showed a trend to decrease IMVD. Neither IMVD-CD105
nor IMVD-CD34 showed a prognostic influence in this study
of predominantly large HCCs.
    Blood vessels could provide support for oxygen and
nutrients, as well as many paracrine factors to its surrounding
tumor cells[1,33,34]. Although it has been well accepted that tumor
growth is dependent on angiogenesis[1], whether IMVD could
truly reflect the angiogenic activity of tumors remains
controversial. As pointed out by a recent review on IMVD from
Folkman’s group[7], IMVD reflects intercapillary distance, and
therefore it may reflect the metabolic need of its surrounding
tumor cells. While our finding of a lower IMVD in larger tumors
should not be interpreted as suggesting that a bigger size
tumor is less angiogenesis dependent, it may, however,
indicate that tumor cells in a bigger sized tumor adapt to
survive with less metabolic demand. It has been reported that
oxygen consumption was much less in tumor tissues as
compared with normal counterparts[1,35]. Another plausible
explanation is that the turnover of tumor cells is much shorter
than that of endothelial cells, resulting in an increased
intercapillary distance as the tumor size increases[36,37]. This
is particularly interesting in the case of HCC, which could
grow very much larger in size compared to other types of
tumors, as indicated by a mean diameter of 8.0 cm in our group
of patients. Our results seem to support the notion that as the
tumor cells expand in HCC, they can become more and more
accustomed to a lower metabolic demand with an increase in
IMVD-34 (/0.74 mm2)
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tumor size[35].
      The adjacent non-tumorous livers were also included in
this study. Interestingly, when we segregated the patients by
CD105 stained vessel patterns in the adjacent non-tumorous
livers according to the presence or absence of a well-diffuse
pattern, the disease-free survival in those patients with a diffuse
pattern of CD105 staining in the adjacent non-tumorous livers
was statistically worse than that of patients without a diffuse
pattern of CD105 expression in the adjacent non-tumorous
livers. The finding that the diffuse pattern of CD105 staining in
the adjacent non-tumorous liver can predict early recurrence is
interesting but not surprising, because unlike other cancer
types, the adjacent non-tumorous tissues in HCC patients were
not normal in most cases. The liver of HCC patients is usually
infected with chronic hepatitis B or C viruses, which lead to
chronic hepatitis or even cirrhosis. Angiogenesis might have an
important role in these disease processes too. Angiogenesis in
the non-tumorous liver may enhance the growth of intrahepatic
metastasis or development of multicentric tumors, both of which
contribute to postoperative recurrence. Although the exact
mechanism is unknown, our data suggest that the detection of
the diffuse pattern of CD105 in the adjacent non-tumorous liver
represents an unfavorable factor to those patients recovering
from HCC resection. The relationship between angiogenesis in
the non-tumorous liver and postoperative recurrence of HCC
warrants further investigation.
      In conclusion, contrary to those reported on other types of
cancers where CD105 was found to be a good prognostic marker
or even better than CD34, our data showed that IMVD-CD105
in HCC did not correlate with the prognosis of patients.
However, our data illustrated that CD105 could stain a subset
of microvessels differently from that stained by CD34 in HCC
tissues. Our clinicopathological analysis demonstrated that
lower scores of IMVD-CD105 were found in larger sized and
more aggressive tumors. Furthermore, different from CD34,
CD105 could also stain microvessels in the adjacent non-
tumorous liver. The presence of well-diffuse patterns of CD105
expression in the adjacent non-tumorous liver could predict
early disease recurrence. Further studies are merited to clarify
the mechanisms involved in these associations.
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